Brief: Travere Therapeutics Enters Into Exclusive Licensing Agreement With Everest Medicines For Civorebrutinib A Potential Best-In-Class Btk Inhibitor For Rare Kidney Diseases
02/06/2026 12:16
BRIEF-Travere Therapeutics Enters Into Exclusive Licensing Agreement With Everest Medicines For Civorebrutinib A Potential Best-In-Class Btk Inhibitor For Rare Kidney Diseases June 2 (Reuters) - Travere Therapeutics Inc TVTX.O:
TRAVERE THERAPEUTICS ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH EVEREST MEDICINES FOR CIVOREBRUTINIB A POTENTIAL BEST-IN-CLASS BTK INHIBITOR FOR RARE KIDNEY DISEASES
TRAVERE THERAPEUTICS - EVEREST TO RECEIVE $112.5 MILLION UPFRONT FOR CIVOREBRUTINIB RIGHTS
TRAVERE THERAPEUTICS - EVEREST ELIGIBLE FOR UP TO $1.03 BILLION IN ADDITIONAL MILESTONE PAYMENTS
TRAVERE THERAPEUTICS - TO PAY TIERED ROYALTIES ON FUTURE CIVOREBRUTINIB SALES
Source text: ID:nBw54m8N0a
Further company coverage: TVTX.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule